Pancreatic Adenocarcinoma Is Different From a Pancreatic Neuroendocrine Tumor
Most pancreatic cancers are pancreatic ductal adenocarcinomas, which arise from the exocrine ductal system. Pancreatic neuroendocrine tumors begin in hormone-producing cells and have different grading, imaging and treatment pathways. Acinar-cell carcinoma, solid-pseudopapillary neoplasm and other uncommon tumors also require specialized review. This page focuses on exocrine pancreatic adenocarcinoma; Sunridge has a separate euroendocrine cancer treatment pathway.
For pancreatic adenocarcinoma, one of the first questions is whether the tumor is resectable, borderline resectable, locally advanced or metastatic. A high-quality pancreatic-protocol CT and multidisciplinary review help define the relationship to the superior mesenteric artery and vein, portal vein, celiac axis and other structures. Surgical judgment can vary, so expert review at an experienced pancreatic center can change the sequence.
Surgery Within a Systemic Plan
Whipple, distal or total pancreatectomy may be considered, often with chemotherapy before or after surgery depending on anatomy, risk and patient fitness.
Treat First, Then Reassess
Preoperative combination therapy can address occult disease and test tumor behavior before a complex operation is reconsidered.
Control Disease and Revisit Local Options
Systemic therapy is central. Selected patients may later be reassessed for radiation, ablation, surgery or a clinical trial at an experienced center.
Systemic Treatment Plus Active Support
Combination chemotherapy, biomarker-directed therapy, clinical trials and symptom care can be coordinated around disease pace and quality-of-life priorities.
Imaging, Tissue, Genetics and Molecular Testing Can Change the Plan
Evaluation commonly includes pancreatic-protocol CT or MRI, chest imaging, liver and kidney tests, bilirubin, blood counts, glucose and CA 19-9 interpreted in context. Endoscopic ultrasound can obtain tissue and assess local anatomy. CA 19-9 is useful for many patients but is not cancer-specific, can rise with bile-duct obstruction and is not produced by everyone; it should not replace imaging and clinical assessment.
Every person with pancreatic adenocarcinoma should discuss germline testing because inherited changes in BRCA1, BRCA2, PALB2, ATM and other genes can influence treatment, clinical trials and family counseling. Tumor profiling may identify somatic BRCA/PALB2 changes, mismatch-repair deficiency or MSI-high disease, NTRK, BRAF or RET alterations, KRAS G12C and rare NRG1 fusions. Most pancreatic cancers carry common KRAS alterations that are still difficult to target, but the actionable minority matters. Learn more about diagnostic testing used in Sunridge cancer care.
A Rare Biomarker Can Be Clinically Important
Olaparib is an FDA-approved maintenance option for selected patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose cancer has not progressed after at least 16 weeks of first-line platinum chemotherapy. In 2024, the FDA also granted accelerated approval to zenocutuzumab for previously treated advanced NRG1 fusion-positive pancreatic adenocarcinoma.
Systemic Treatment, Surgery, Radiation and Trials Each Have a Role
For fit patients with localized or advanced disease, combination chemotherapy may include modified FOLFIRINOX, NALIRIFOX or gemcitabine plus nab-paclitaxel, chosen according to the setting, previous therapy, performance status, bilirubin, neuropathy, organ function and goals. Surgery offers the clearest chance of long-term control when complete removal is feasible, but systemic therapy remains important because microscopic disease can exist before it appears on scans.
Radiation or chemoradiation may help selected patients with localized, borderline-resectable or locally advanced disease, and can also relieve pain. At progression, treatment can shift to a non-cross-resistant regimen, a biomarker-matched therapy or a clinical trial. Biliary stents, gastric or duodenal interventions, celiac-plexus procedures, ascites management, diabetes care and palliative medicine are active treatments that can improve function and make anticancer therapy more tolerable.
Before Surgery
Clarify vascular anatomy, occult metastatic risk, biliary drainage, nutrition, physical reserve and whether neoadjuvant therapy offers a better sequence.
After Surgery
Address pathology, margins, lymph nodes, recovery, pancreatic enzymes, glucose control, weight and readiness for postoperative systemic therapy.
Advanced Disease
Choose therapy around fitness, symptoms, bilirubin, neuropathy, prior exposure and molecular findings while treating pain and malnutrition early.
After Progression
Reassess the diagnosis, prior benefit and toxicity, germline and tumor testing, clinical trials, local complications and the patient’s priorities.
Protect Digestion, Weight, Muscle and Daily Function From the Beginning
An individualized integrative plan may address:
- Pancreatic-enzyme replacement with meals and snacks when indicated
- Protein, calories and meal timing for weight stability
- Diarrhea, greasy stools, bloating, nausea and early fullness
- Glucose changes and diabetes after pancreatic injury or surgery
- Walking and resistance exercise adapted to fatigue and treatment
- Pain, neuropathy, sleep, anxiety and emotional distress
- Recovery before and after Whipple or distal pancreatectomy
- Every herb, extract, vitamin and supplement being used
Natural and supportive care can be practical, active and hopeful. Nutrition is not simply “eat more”: pancreatic exocrine insufficiency can prevent a person from absorbing food. Prescription pancreatic enzymes, correctly timed and dosed, may reduce steatorrhea and improve nutrient absorption. Smaller energy-dense meals, adequate protein, individualized fat intake, hydration and symptom-directed anti-nausea or bowel support can help preserve weight and strength.
Appropriately adapted walking and resistance exercise may help maintain function and muscle. Mindfulness, relaxation, yoga and acupuncture for selected symptoms can be considered as part of supportive care. These interventions can be coordinated thoughtfully with effective surgery, systemic treatment, biliary drainage, pain procedures, enzyme replacement or urgent management of complications.
Natural Products Must Fit Chemotherapy, Surgery and Pancreatic Function
Concentrated botanicals and supplements can affect platelets, bleeding, anesthesia, liver enzymes, glucose and drug metabolism. This is especially important around a Whipple procedure and during irinotecan-, fluorouracil-, oxaliplatin-, gemcitabine- or taxane-based treatment. St. John’s wort can lower exposure to several medicines, while grapefruit and other CYP-modifying products can alter drug levels. High-dose antioxidants during chemotherapy remain controversial and should not be assumed harmless.
Fasting, juice-only regimens and restrictive “anticancer” diets can accelerate weight and muscle loss. Probiotics may not be appropriate during severe neutropenia or with certain central-line or infection risks. Sunridge documents the exact product, brand, dose and timing; checks it against treatment and organ function; introduces changes deliberately; and monitors weight, bowel patterns, glucose, liver tests, blood counts and symptoms.
Before Surgery
Review products that affect bleeding, blood pressure, glucose, anesthesia or wound healing. The surgical team decides when each should stop and restart.
During Combination Chemotherapy
Track hydration, diarrhea, nausea, neuropathy, blood counts, liver function and enzyme needs before adding products that may complicate toxicity.
With Bile-Duct Obstruction
Prioritize drainage and infection assessment. Herbal “liver cleanses” cannot open an obstructed duct and may add liver injury.
With Weight Loss or Steatorrhea
Assess pancreatic-enzyme timing and dose, calorie and protein intake, glucose, deficiencies and reversible causes before imposing dietary restrictions.
What We Review
Helpful records include the pathology report and slides when available, pancreatic-protocol CT or MRI reports and images, endoscopic-ultrasound findings, operative notes, surgical pathology, radiation details, biliary or duodenal procedures, CA 19-9 trends and a complete treatment timeline with response and toxicity.
Please include germline testing, tumor sequencing and MSI/MMR results, current blood counts and kidney and liver tests, bilirubin, glucose or A1c, weight history, pancreatic-enzyme prescription and every medicine, herb and supplement. We also want to understand stool changes, appetite, nausea, pain, neuropathy, sleep, activity, emotional health, caregiver needs and the goals most important to the patient. You may also review our Stage 4 cancer guide and cancer treatment resources before your call.
Questions About Integrative Pancreatic Cancer Care
Can Stage IV pancreatic cancer still be treated?
Yes. Metastatic pancreatic cancer is serious, but systemic therapy can shrink or control disease and relieve symptoms. Biomarker-directed treatments and clinical trials may apply to a subset of patients, while nutrition, pain control and palliative care can improve function throughout treatment.
Can natural therapies cure pancreatic cancer?
No natural therapy has been proven to replace surgery or effective systemic treatment. Integrative care may support digestion, weight, strength, symptoms, recovery and quality of life while being honest about what is supported and what remains uncertain.
How do I know whether I need pancreatic enzymes?
Greasy or floating stools, diarrhea, bloating, excessive gas, weight loss and difficulty maintaining nutrition can suggest pancreatic exocrine insufficiency. Surgery and the tumor itself can contribute. Evaluation and correct prescription-enzyme timing are important.
Should everyone with pancreatic cancer have genetic testing?
Every person with pancreatic adenocarcinoma should discuss germline testing, and advanced cancers should be considered for tumor molecular profiling. Results can affect treatment, clinical-trial eligibility and relatives’ risk assessment.
Can I come to Sunridge during FOLFIRINOX, NALIRIFOX or gemcitabine-based treatment?
Potentially. Many people seek integrative support during active therapy. The plan must be coordinated around blood counts, bilirubin, bowel function, neuropathy, glucose, nutrition, treatment timing and drug–supplement interactions.
Will Sunridge coordinate with my pancreatic cancer team?
Yes. Coordination is important because surgery, chemotherapy, radiation, stents, enzymes, diabetes care, scans, biomarkers, nutrition and natural products affect one another.
References
- National Cancer Institute. Pancreatic Cancer Treatment (PDQ®)—Health Professional Version.
- National Cancer Institute. Pancreatic Cancer Treatment (PDQ®)—Patient Version.
- National Cancer Institute. Advances in Pancreatic Cancer Research.
- National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing.
- U.S. Food and Drug Administration. Olaparib prescribing information, including metastatic pancreatic adenocarcinoma.
- U.S. Food and Drug Administration. Zenocutuzumab for NRG1 fusion-positive pancreatic adenocarcinoma, 2024.
- European evidence-based guideline for pancreatic exocrine insufficiency and enzyme replacement, 2024.
- Best supportive care in advanced pancreatic cancer: systematic review and patient-care bundle.
- Exercise medicine in pancreatic cancer: systematic review.
- Exercise therapy in pancreatic cancer: systematic review and meta-analysis.
- Society for Integrative Oncology–ASCO guideline for anxiety and depression in adults with cancer.
- National Cancer Institute. Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ®).
This page is educational and does not replace diagnosis or treatment advice from a qualified pancreatic surgeon, medical oncologist, radiation oncologist, gastroenterologist, genetic counselor or multidisciplinary team. Treatment outcomes cannot be guaranteed.